Multiple drug-susceptibility screening in Mycobacterium bovis: new nucleotide polymorphisms in the embB gene among ethambutol susceptible strains  by Marianelli, Cinzia et al.
International Journal of Infectious Diseases 33 (2015) 39–44Multiple drug-susceptibility screening in Mycobacterium bovis:
new nucleotide polymorphisms in the embB gene among
ethambutol susceptible strains
Cinzia Marianelli a,*, Federica Armas a, Maria Beatrice Boniotti b, Piera Mazzone c,
Maria Lodovica Pacciarini b, Vincenzo Di Marco Lo Presti d
aDepartment of Food Safety and Veterinary Public Health, Istituto Superiore di Sanita`, Rome, Italy
bNational Reference Centre for Mycobacterium bovis tuberculosis, Istituto Zooproﬁlattico Sperimentale della Lombardia e dell’Emilia Romagna, Brescia, Italy
c Istituto Zooproﬁlattico Sperimentale dell’Umbria e delle Marche, Department of Research and Development, Perugia, Italy
d Istituto Zooproﬁlattico Sperimentale della Sicilia, Sez. Diagn. Barcellona Pozzo di Gotto, Italy
A R T I C L E I N F O
Article history:
Received 10 September 2014
Received in revised form 19 December 2014
Accepted 22 December 2014








S U M M A R Y
Objectives: Pyrazinamide-resistant Mycobacterium bovis isolates of animal origin were assessed for drug
susceptibility to ﬁve antituberculosis drugs by the agar based Middlebrook 7H11 method as gold
standard as well as by a simpliﬁed, dichotomous resazurin microtitre assay (d-REMA).
Methods: A total of 53 M. bovis isolates were typed and tested against isoniazid, rifampin, streptomycin,
ethambutol, kanamycin and the control drug pyrazinamide. On the basis of the results obtained, pncA
and embB genes were PCR-ampliﬁed and DNA-sequenced for all isolates.
Results: All M. bovis isolates, classiﬁed into 21 spoligotype/MIRU-VNTR proﬁles, were resistant to
pyrazinamide by both methods, as expected. The pncA gene sequencing conﬁrmed the presence of the
resistance-conferring H57D mutation. All strains were found to be susceptible to the other ﬁve drugs by
the agar based gold standard method. The d-REMA was in agreement with these results for all ﬁve drugs,
with the exception of 12 isolates, which showed ambiguous and therefore inconclusive results in
ethambutol testing. Mutations in the embB gene were observed in all 53 isolates: four new single-
nucleotide polymorphisms were identiﬁed. No association was found between embB genetic proﬁles and
ethambutol resistance results by the gold standard.
Conclusion: All M. bovis isolates were sensitive to the most common antituberculosis drugs used for
treatment. There was a good agreement between the d-REMA assay and the agar based reference
method. Among ethambutol susceptible isolates, four new embB mutations were found.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Mycobacterium bovis, the main etiological agent of bovine
tuberculosis, is a pathogen of signiﬁcant importance in livestock
and wild animal species worldwide. It is also known to cause
tuberculosis in humans that is both clinically and pathologically
indistinguishable from that caused by M. tuberculosis.1
In most industrialised countries, animal test-and-slaughter
schemes have successfully reduced the prevalence of bovine* Corresponding author. Department of Food Safety and Veterinary Public Health,
Istituto Superiore di Sanita`, Viale Regina Elena 299, 00161 Rome, Italy.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).tuberculosis, and cases of M. bovis infection in humans are
relatively rare. In non-industrialised countries, the situation is
profoundly different. In the absence of control programs preva-
lence rates of tuberculosis in livestock have increased. Communi-
ties living in close contact with livestock, consuming mostly
unpasteurised milk and dairy products that may derive from
infected cattle herds, or communities with high HIV/AIDS infection
rates, are those facing a higher risk of M. bovis infection.2,3
Although M. bovis causes considerably less human tuberculosis
than M. tuberculosis, its potential impact on high-risk populations
should not be underestimated.
The most common antibiotics used against tuberculosis are:
pyrazinamide (PZA), isoniazid (INH), rifampin (RIF) and ethambu-
tol (EMB), followed by streptomycin (STR) and kanamycin (KAN).
M. bovis is known to be naturally resistant to PZA. The presence of aciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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confers natural resistance to PZA in M. bovis. 4 Recently, an
emerging trend in the incidence of INH-resistant M. bovis was
reported in Ireland.5 Outbreaks caused by multidrug-resistant M.
bovis strains – resistant, at least, to INH and RIF – are also
documented in the literature and their impact has been dramatic.
6–10 Rapid and reliable methods for early detection of drug
resistance in tuberculosis are thus vital.
Conventional drug susceptibility tests for M. tuberculosis
include the proportion method on either Lowenstein Jensen
medium or Middlebrook 7H10 agar 11,12 and the radiometric
method. 13,14 Although these methods are used globally, they are
laborious and time-consuming, requiring three to six weeks to
yield results. In recent years, several new approaches, both
phenotypic and genotypic, have been proposed for a faster
detection of drug-resistant tuberculosis.15–17 Using various
molecular methods, mutations in the following genes have been
identiﬁed as associated with resistance to the following antitu-
bercular drugs: the rpoB gene, with RIF-resistance; the katG gene
and the promoter region of the mabA-inhA operon, with INH-
resistance; the embB gene, with EMB-resistance; the pncA gene,
with PZA-resistance; the rpsL and rrs genes, with STR-resistance;
and the rrs, eis and whiB7 genes, with KAN-resistance. 18,19 Among
molecular methods, DNA sequencing is the most direct and reliable
for the detection of both known and novel mutations. As a method
for the routine diagnosis of drug resistance however, molecular
methods are expensive and impractical.
Colorimetric assays employing speciﬁc reagents to produce a
change in colour have been described, 20–22 and recently
recommended by the WHO. 23 Among these, the resazurin
microtitre assay (REMA), based on the oxidation-reduction dye
resazurin, was successfully tested on clinical isolates of M.
tuberculosis against ﬁrst- and second-line antitubercular drugs
with very good results obtained after only eight days. 21,24–31 REMA
is considered fast, inexpensive – since no special apparatus is
needed – and relatively easy both to perform and to interpret in
comparison with conventional methods.
While mycobacteria isolated from human cases are routinely
assessed for drug susceptibility, studies regarding the resistance
assessment of M. bovis isolated from animals to antibiotics used to
treat human tuberculosis are limited. 32,33 M. bovis may spread to
humans through the respiratory route and through the consump-
tion of contaminated meat and dairy products. 2 Farmers and
veterinarians are at a higher risk of infection. The drug
susceptibility of M. bovis strains isolated from livestock should
therefore be routinely assessed in infected herds so as to prevent
the transmission to humans of multidrug-resistant M. bovis and
control outbreaks.
In this study, we assessed animal M. bovis susceptibility to six
antitubercular drugs by both the gold standard agar proportion
method and a simpliﬁed REMA plate method – which we named d-
REMA test.
2. Materials and Methods
2.1. M. bovis strains and molecular typing
A total of 53 M. bovis isolates from the lymph nodes of black pigs
(n = 34), head of cattle (n = 18) and sheep (n = 1) were analysed for
susceptibility to INH, RIF, STR, EMB, KAN and PZA. All infected
animals originated from a restricted area comprising the Nebrodi
Natural Park and its surroundings, in northeastern Sicily. Lymph
node and tissue samples were collected between 2007 and 2011 at
the abattoir during the postmortem inspection aimed to detect
macroscopic lesions suggestive of tuberculosis, in accordance with
national laws. Culture tests were performed from collected tissuesand the isolates were characterized by DNA sequencing. No speciﬁc
permissions were required for these activities. The genetic proﬁles
of 31 of the M. bovis isolates (from black pigs) had been determined
previously by our group. 34 All other isolates similarly underwent
both spoligotyping and 12-loci MIRU-VNTR analysis in the
framework of the present study, following the same procedure. 34
2.2. Drug susceptibility testing
Isolates were subcultured in Middlebrook 7H9 medium (Biolife,
Italy) with 10% oleic acid-albumin-dextrose-catalase (OADC)
enrichment (Becton Dickinson and Company) before being tested.
Drug solutions were prepared at concentrations of 20 mg/ml (PZA;
Sigma-Aldrich, UK) and 2 mg/ml in distilled water (INH, STR, EMB,
and KAN; Sigma-Aldrich, UK) or methanol (RIF; Sigma-Aldrich,
UK), ﬁlter sterilised, and frozen until used. The drug-sensitive M.
bovis ATCC 19210 was used as negative control. Since no resistant
M. bovis strains were available to our laboratory, an M. avium strain
resistant to both INH and EMB from our bacteria collection was
included in the study. In addition, all M. bovis, whose natural
resistance to PZA is well known, were tested against this drug by
both agar proportion and d-REMA. We considered PZA resistance
as our internal positive control.
2.2.1. Drug susceptibility by the gold standard agar proportion
method in Middlebrook 7H11 medium
The approved standard (M24A) for Susceptibility Testing of
Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes
published by the Clinical and Laboratory Standards Institute (CLSI)
was followed. 35 Brieﬂy, the turbidity of the inoculum was adjusted
to match a 1.0 McFarland standard, and diluted 1:100 and
1:10,000. One hundred ml of these solutions were then inoculated
into 35 mm Middlebrook 7H11 agar plates with and without the
test drug. The following ﬁnal critical drug concentrations were
used: 0.2 mg/ml for INH; 1.0 mg/ml for RIF; 7.5 mg/ml for EMB;
2.0 mg/ml for STR; 6.0 mg/ml for KAN; and 100 mg/ml for
PZA29. After three weeks of incubation at 37 8C in 5% CO2, the
number of colony forming units (CFU) growing on the drug-
containing medium was compared with those growing on the
drug-free medium and expressed as a percentage of the latter. The
isolate was considered resistant if the number of colonies on a
medium containing an antimicrobial agent, relative to that
observed on a drug-free medium (control) was 1%.
2.2.2. Dichotomous REMA testing (d-REMA)
The test, based on the work by Palomino and colleagues, 21 was
carried out in triplicate in 96-well plates. Middlebrook 7H9
medium, supplemented with 0.1% Casitone (Biolife, Italy) and
OADC, was prepared according to the manufacturer’s instructions.
To test resistance to PZA, the pH was adjusted to 6.0. One hundred
microlitres of the medium were inoculated into each well.
Bacterial suspensions (for each of the 53 test isolates and the
two control strains) were adjusted to a 1.0 McFarland standard,
diluted 1:20 in the same medium and inoculated (100 ml). The
antitubercular drugs were subsequently added. Two ﬁnal con-
centrations were tested per drug: one is the drug’s cutoff value for
resistance in REMA (R), the other is the value of REMA drug
susceptibility (S). The R value corresponds to the lowest drug
concentration found in REMA for those strains classiﬁed as
resistant by the gold standard proportion method; 21,24–26,28,29
the S value is, instead, the highest drug concentration found in
REMA for those strains classiﬁed as sensitive by the gold standard
proportion method. 21,24–26,28,29 The drug concentrations used are
shown in Table 1. A growth control containing no drug and a sterile
control without bacteria were also included. Plates were covered
with lids, placed in a plastic bag and incubated at 37 8C in 5% CO2
Table 1
Final drug concentrations used for d-REMA susceptibility testing
Drug Drug concentration cutoff values
(mg/ml) for:
Reference N8 for (R) value
Susceptibility (S) Resistance (R)
INH 0.1 0.25 25,28
RIF 0.25 0.5 21,28
STR 0.5 1.0 25
EMB 2.5 3.125 26
KAN 2.5 3.125* 24
PZA 100.0 800.0 29
* Considering the fact that the approved standard CLSI document M24-A for the
agar proportion method recommends identical cutoff concentrations for KAN and
EMB (albeit for cultures on Middlerbrook 7H10 agar medium), we used the EMB
breakpoint concentration for our d-REMA tests on KAN instead of 5.0 mg/ml cited by
Martin et al., 24
Table 2
Primers used for PCR and sequencing
Gene Forward, Reverse and Sequencing primers Size (bp)
pncA F 50- GATCATCGTCGACGTGCAGA-30
R 50-GAGCTGCAAACCAACTCGAC-30
540










Genetic proﬁles of M. bovis isolatesa
Spoligotype/MIRU-VNTR typeb Origin (n) Reference N8
SB0120/a (4,5,5,3,3,10,4,3,4,3,6,5) black pig (10) 34






SB0120/c (4,5,5,3,3,10,4,4,4,3,6,4) black pig (1) 34
SB0120/d (4,5,5,3,3,10,3,4,4,3,8,5) black pig (1) 34




SB0120/f (5,5,5,3,3,10,4,4,4,3,6,5) black pig (1) 34




SB0120/j (5,3,5,3,3,10,4,4,3,3,6,5) cattle (1) present study
SB0120/k (4,5,5,3,5,10,4,4,4,3,6,5) cattle (1) present study
SB0120/l (5,4,5,3,3,10,4,4,4,3,4,5) cattle (2) present study
SB0120/m (4,5,5,3,3,10,4,4,4,3,8,5) cattle (1) present study
SB0120/n (5,5,6,3,3,10,4,4,4,3,6,5) cattle (1) present study
SB0841/f (5,5,5,3,3,10,4,4,4,3,6,5) black pig (3) 34
SB0841/h (5,5,5,3,3,10,4,4,4,3,5,5) black pig (1) 34




SB0841/o (5,5,5,3,3,10,4,4,4,3,7,5) cattle (1) present study
SB0841/p (5,5,5,3,3,10,4,4,4,3,7,4) cattle (1) present study




SB0833/a (4,5,5,3,3,10,4,3,4,3,6,5) black pig (2) 34
SB2018/h (5,5,5,3,3,10,4,4,4,3,5,5) black pig (1) 34
SB0133/f (5,5,5,3,3,10,4,4,4,3,6,5) cattle (1) present study
a N = 53. Throughout, n represents the number of isolates.
b Genotypes obtained by combining spoligotyping and MIRU-VNTR results. The
repeat copy number at each locus is indicated in brackets, as previously reported.34
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solution (Acros Organics,USA) was added to each well. The plates
were incubated overnight at 37 8C and assessed for colour
development. A change from blue to pink indicated reduction of
resazurin and therefore bacterial growth. The strain was classiﬁed
as resistant if bacterial growth was observed in both concentra-
tions (S and R); on the contrary, if growth was observed in the S
concentration only, or in neither, the isolate was classiﬁed as
susceptible to the drug in question. Isolates showing resistance by
the d-REMA assay underwent minimum inhibitory concentration
(MIC) testing by the full REMA method, as described below.
2.2.3. MIC by full REMA
This step was to be performed only in case any of the isolates
were found to be resistant to one or more of the study drugs by the
REMA assay. Since bacterial growth was observed only in the
presence of EMB in the d-REMA assay (see results), MIC testing was
carried out only for this drug. The test was carried out according to
Palomino and colleagues. 21 Ten dilutions were tested (0.5, 1.0, 1.5,
2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5 mg/ml). The MIC was deﬁned as the
lowest drug concentration that prevented resazurin colour change
from blue to pink.
2.3. DNA sequencing
Sequencing, too, was to be performed only in case of drug
resistance. Since resistance in the d-REMA assay but not the gold
standard assay was observed only to the test drug EMB and to the
control drug PZA (see results), The embB and pncA genes, the most
common target genes associated with resistance to these drugs
respectively, were PCR ampliﬁed. The reference sequence acces-
sion number (AC) NC_002945 of M. bovis AF2122/97 available at
NCBI was used to design primers. PCR ampliﬁcations were carried
out in 50-ml volumes using GoTaq DNA Polymerase (Promega
Corporation, Madison, WI) following the manufacturer’s instruc-
tions. PCR was performed under the following conditions:
denaturation at 94 8C for 2 min, followed by 30 cycles at 94 8C
for 30 s, 58 8C for 30 s and extension at 72 8C for either 4 min
(embB) or 1 min (pncA).
After the last cycle, samples were incubated for seven
additional minutes at 72 8C before they were stored at 4 8C. PCR
products were analysed by 2% agarose gel electrophoresis, stained
with GelRed Nucleic Acid Stain (Biotium Inc., Hayward, CA),
puriﬁed by ExoSAP-IT PCR Product Cleanup (Affymetrix, CA) and
sequenced. PCR and sequencing primers used are listed in
Table 2. Sequences were analysed using the ABI Prism SeqScape
Software, version 2.0 (Applied Biosystems, Foster City, CA). All
consensus sequences generated were then compared to the
published, drug-sensitive M. tuberculosis H37Rv reference strain,to detect genetic variation. Mutations were conﬁrmed through
resequencing. To distinguish silent from missense mutations,
amino acid sequences were theoretically deduced.
3. Results
3.1. Molecular typing of isolates
The genetic proﬁles of all 53 M. bovis isolates of animal origin
included in the study are shown in Table 3. The isolates were
classiﬁed into ﬁve spoligotypes (SB0120, SB0841, SB0833, SB2018
and SB0133) and 17 MIRU-VNTR types (a-q) – which, when
combined, yielded 21 genetic proﬁles. Proﬁles SB0120/a and
SB0120/b (10 and 14 isolates, respectively) were the most
frequent.
3.2. Drug susceptibility and DNA sequencing of drug target genes
Drug susceptibility results were available after 21 and eight
days of incubation for the agar proportion and the d-REMA
method, respectively.
Figure 2. Drug susceptibility to INH, RIF, STR, EMB and KAN by d-REMA. A-C, D-F, G-
H: sample triplicates. L-N: M. avium strain resistant to both INH and EMB in
triplicates. O: negative controls (uninoculated broth with drug). 1-2: 0.1 (S) and
0.25 (R) mg/ml for INH; 3-4: 0.25 (S) and 0.5 (R) mg/ml for RIF; 5-6: 0.5 (S) and 1.0 (R)
mg/ml for STR; 7-8: 2.5 (S) and 3.125 (R) mg/ml for EMB: 9-10: 2.5 (S) and 3.125 (R)
mg/ml for KAN; (+) positive control containing no drug; (-) negative control
containing uninoculated media.
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avium strain to INH and EMB (Figure 2 lines L-N) was conﬁrmed by
both methods, as was the susceptibility of M. bovis ATCC to all test
drugs.
Nucleotide sequence analysis of the pncA gene conﬁrmed the
presence of the substitution of CAC for GAC at codon 57 (mutation
H57D) in all strains.
The two methods yielded concordant results also as far as the
susceptibility of M. bovis to INH, RIF, STR and KAN, ﬁnding all
isolates sensitive to these drugs. With respect to EMB however,
some of the results obtained were discordant: while 43 strains
were found to be susceptible by both methods, the remaining
12 isolates were sensitive only by the agar proportion method. The
d-REMA method gave inconclusive results for these 12 isolates, in
that the resazurin blue dye was reduced to the mauve colour rather
than to pink (Figure 2, column 8, lines A-G). In the hope of gaining
insight into the mechanisms underlying these results, we then
sequenced, in all isolates, the embB gene, a gene encoding an
enzyme (arabinosyl transferase) targeted by EMB. Nucleotide
sequences of all isolates were compared to the reference strain M.
bovis AF2122/97 available in GenBank. Four single-nucleotide
polymorphisms (SNPs) were found: one synonymous – nucleotide
substitution CTG ! CTA at codon 220 (silent mutation, SNP1) – and
three non-synonymous – ACG ! AAG at codon 610 (mutation
T610K, SNP2), CAG ! CGG at codon 998 (mutation Q998R, SNP3),
and TTC ! TCC at codon 1012 (mutation F1012S, SNP4). None of
the above SNPs have been previously described in the literature to
our knowledge. As shown in Table 4, 21/53 isolates carried SNP1
alone, 29/53 carried SNP1 and SNP2, 2/53 SNP1 and SNP3, and 1/53
SNP1, SNP2 and SNP4. The SNP1 mutation was found in all M. bovis
isolates. The 12 strains that turned the resazurin blue dye to the
mauve colour had either SNP1 alone (n = 5), SNP1 with SNP2
(n = 6), or SNP1 with SNP3 (n = 1). None of the above SNPs were
found in the embB nucleotide sequence of the drug-sensitive M.
bovis ATCC, which was identical to that of the reference strain M.
bovis AF2122/97. We also assessed the susceptibility of the
12 strains in question to EMB by the full REMA method. We
found no correlation between embB mutations and resazurin
phenotypes: the blue-to-mauve colour change occurred at MIC
values ranging from 2.5 to 4.0 mg/ml, and was independent of
SNPs. Our positive control, the M. avium resistant to EMB, was able
to grow at the highest drug concentration tested.
4. Discussion
Drug susceptibility of M. tuberculosis complex isolated from
clinical samples is routinely tested to ensure that the mostFigure 1. Drug susceptibility to PZA by d-REMA. A-C, D-F: sample triplicates. 1-2, 5-
6, 9-10: 100.0 (S) and 800.0 (R) mg/ml for PZA; (+) positive control containing no
drug; (-) negative control containing uninoculated medium.appropriate antimicrobial therapy is administered to patients.
These tests are rarely carried out on M. bovis and other
Mycobacterium isolates of animal origin. Multidrug-resistant M.
bovis outbreaks have occurred however, with dramatic conse-
quences. 6–10 Drug susceptibility surveillance of M. bovis from
animals is therefore necessary to prevent the transmission to
humans of multidrug-resistant strains and to control possible
outbreaks.
In this study we tested the susceptibility of 53 M. bovis isolates
to six antibiotic drugs commonly administered to human
tuberculosis patients: INH, RIF, STR, EMB, KAN and PZA. This is
the ﬁrst report on drug susceptibility of M. bovis isolates of animal
origin, as measured by the REMA plate method. The REMA plate
method proposed by Palomino and colleagues 21 was used here
with slight modiﬁcations: rather than testing each strain against
serial dilutions of each drug to deﬁne its MIC, we prepared 96-well
plates testing only two concentrations per drug per isolate: the
cutoff value for drug resistance, R, and the cutoff value of REMA
drug susceptibility, S. 24,28,29 The R values were determined inTable 4










embB CTG ! CTA 21
CTG ! CTA ACG ! AAG 29
CTG ! CTA CAG ! CGG 2
CTG ! CTA ACG ! AAG TTC ! TCC 1
n, number of isolates (N = 53).
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method. We thus used this simpliﬁed method, the d-REMA, for an
easier classiﬁcation of isolates as either drug resistant or
susceptible. No positive control was included for RIF, KAN or
STR but one for both INH and EMB. This is a limitation of our study.
M. bovis is known to be naturally resistant to PZA due to a
mutation in the pncA gene whereby histidine57 (His57) is replaced
by aspartate (Asp), a mutation used as a genetic marker for the
rapid differentiation of bovine and human tubercle bacilli. 36 As
expected, all 53 isolates were resistant to PZA by both methods.
Nucleotide sequence analysis of the pncA gene conﬁrmed the
presence of the H57D mutation.
The strains were susceptible to all other drugs by the standard
method. Concordant results were obtained for INH, RIF, STR and
KAN by the d-REMA. EMB sensitivity by d-REMA was in agreement
with the results obtained by agar proportion method for most
strains (41/53), but not all. In 12 of the 53 strains tested,
repeatedly, the resazurin blue dye following incubation was
neither blue (susceptible) nor pink (resistant) but somewhere in-
between (mauve), as shown in Figure 2, and the test resulted
therefore inconclusive.
The rapid increase in M. tuberculosis resistance to EMB threatens
the diagnosis and treatment of tuberculosis. Resistance to EMB is
caused by mutation of the embCABoperon (embC, embA, and embB)
that encodes membrane-associated arabinosyltransferases. Muta-
tions associated with both natural and acquired high-level
resistance to EMB have been reported to occur more frequently
at codon 306 of the embB gene, with Val, Ile, or Leu substituting the
wild-type Met. 37 Other resistance-conferring mutations of the
gene have been found in codon 406, where the wild-type Gly was
replaced with Ala, Asp, Cys or Ser. 38,39 These mutations represent
therefore promising diagnostic markers for the rapid detection of
EMB resistance. Some mutations of the embC-embA intergenic
region have been identiﬁed in EMB-resistant clinical strains. It has
been recently found that these mutations may contribute to EMB
resistance. 40
Upon sequencing, none of the isolates included in the present
study showed any of the above resistance-associated mutations.
On the other hand, notably, nucleotide mutations were observed in
all 53 isolates. Mutations were identiﬁed at four different loci of
the embB gene: one synonymous SNP (CTG ! CTA) at codon 220
(SNP1), and three non-synonymous SNPs – T610K, Q998R, and
F1012S – at codon positions 610, 998 and 1012, respectively
(SNP2-SNP4). All M. bovis isolates showed SNP1 and most carried
the additional SNP2. To our knowledge these sequence variants
had not been previously described in either resistant or susceptible
members of the M. tuberculosis complex.
We then assessed the MIC of EMB for these 12 strains in search
of possible associations between embB SNPs and resazurin
phenotypes (blue, mauve or pink colour change). Resazurin
blue-to-mauve colour change was observed at EMB ﬁnal con-
centrations of 2.5-4.0 mg/ml for all 12 strains and was associated
with neither spoligotype/MIRU-VNTR genetic proﬁles, nor any of
the above SNPs. We thus considered the sequence variations in
question a genetic polymorphism, unrelated to EMB-resistance
phenotype. Since no multicenter validation study of REMA
compared to the standard agar methods (Middlebrook 7H10 or
7H11 agar plates) has been carried out until now, limitations on
the comparison of EMB results are a potential source for the
discrepancies between the REMA and the reference assay.
However, in light of the results obtained by the agar standard
method performed at the recommended drug critical concentra-
tions, our M. bovis strains, may be considered all EMB-susceptible.
This is in agreement with previous studies where no M. bovis from
animal origin were resistant to any of the antibiotics in question.
33,41 The mauve colour change observed at the EMB-resistancecutoff value suggests that a slight growth of mycobacteria did
occur in some of the strains, a result that the d-REMA test was able
to reveal. It is possible that this ambiguous chromatic change is a
sign of borderline susceptibility as EMB is also a difﬁcult drug to
test with a poor agreement even among supranational reference
laboratories. Future studies are needed to clarify the phenomena
here observed. Conceivably, the embB polymorphism detected
might contribute to resistance if coupled with additional
mutations.
The discrepancy encountered between the results of the agar
proportion method and those of the d-REMA may be due to
different culture conditions (e.g., the use of solid versus liquid
media) affecting the interaction of EMB with the mycobacteria or
to a lack of equivalence or comparability between the drug
concentrations used in the two assays (7.5 versus 3.125 mg/ml).
Discrepancies between the colorimetric assay and the agar
proportion method were also observed in a previous study where
higher levels of resistance were detected for INH, RIF and STR by
the colorimetric method.42
In conclusion, M. bovis isolates of animal origin were sensitive
to all the drugs tested. The d-REMA testing of our isolates against
six anti-tuberculosis drugs gave concordant results with the 7H11
agar proportion method, although it needs to be validated. DNA
sequencing revealed four new SNPs in the embB gene in all strains,
which appear not to be related to EMB resistance.
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